When was Coherus Biosciences founded?

Coherus Biosciences was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Coherus Biosciences located?

Coherus Biosciences is headquartered in Redwood City, United States. It is registered at Redwood City, California.

How many employees does Coherus Biosciences have?

As of Mar 31, 2026, the latest employee count at Coherus Biosciences is 218.

Is Coherus Biosciences a funded company?

Coherus Biosciences is a funded company, having raised a total of $144M across 11 funding rounds to date. The company's 1st funding round was a $***** Convertible Debt round, raised on Jan 25, 2011.

When was the latest funding round of Coherus Biosciences?

Coherus Biosciences' latest funding was a $***** Post IPO round on Apr 14, 2020, with participation from 0 investor.

What is the annual revenue of Coherus Biosciences?

Annual revenue of Coherus Biosciences is between $100M and $500M as on Dec 31, 2024

Where does Coherus Biosciences rank among its competitors?

Coherus Biosciences ranks 53rd amongst 3460 active competitors, of which 1128 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Coherus Biosciences?

Coherus Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Coherus Biosciences - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Website: coherus.com
Registered Address: Redwood City, California

Key Metrics

Founded Year

2010

Location

Redwood City, United States

Stage

Public

Total Funding

$144M in 11 rounds

Latest Funding Round

Post IPO, Apr 14, 2020, $*****

Investors

Venrock & 15 more

Ranked

53^rd among 3460 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2024

Employee Count

218 as on Mar 31, 2026

Investment & Acquisitions

Surface Oncology & 1 more

Similar Companies

BeiGene & 596 more

Exit Details

Public

View Coherus Biosciences' full profile

Coherus Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Coherus Biosciences, Inc. CIN: 214752297 , United States, Active	Jul 14, 2023	-	-	-
Coherus Biosciences, Inc. CIN: 273615821 , United States, Active	Dec 26, 999	$100M - $500M (As on Dec 31, 2024)	239 (As on Dec 31, 2024)	-

Coherus Biosciences got listed on Nov 06, 2014.

Click here to take a look at Coherus Biosciences's IPO in detail

Coherus Biosciences has raised a total funding of $144M over 11 rounds. Its first funding round was on Jan 25, 2011. Coherus Biosciences has 16 institutional investors.

Here is the list of recent funding rounds of Coherus Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 14, 2020	7480486	Post IPO	9435317	8115915	9857405	9852058
Jan 07, 2019	7422218	Conventional Debt	5113210	9373246	2458653	HealthCare Royalty Partners
Dec 12, 2017	4762311	Post IPO	1495058	2024517	9408429	8645193

Access funding benchmarks and valuations. Sign up today!

View details of Coherus Biosciences's funding rounds and investors

Coherus Biosciences' employee count trend

Coherus Biosciences has 218 employees as of Mar 26. Here is Coherus Biosciences's employee count trend over the years:

Employee count trend for Coherus Biosciences

Uncover Coherus Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Coherus Biosciences include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Coherus Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Relay Therapeutics 2016, Cambridge (United States), Public	Developer of drug discovery platform and study protein motion	$520M	BVF Partners, SoftBank Vision Fund & 17 others	71/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
9th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
53rd	Coherus Biosciences 2010, Redwood City (United States), Public	Developer of biosimilar therapeutics	$144M	RA Capital Management, Athyrium Capital Management ... & 14 others	66/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Coherus Biosciences's competitors? Click here to see the top ones

Coherus Biosciences has acquired 2 companies including Surface Oncology and InteKrin Therapeutics. Coherus Biosciences has not made any investments as of now.

Here is the latest report on Coherus Biosciences's sector:

Free

Oncology - Sector Report

Edition: October, 2026 (75 Pages)

View all reports related to Coherus Biosciences

Media has covered Coherus Biosciences for a total of 18 events in the last 1 year, 7 of them have been about company updates and 1 about partnerships.